Date: {{$ActivityAssignDate}}

Dear Dr. {{$doctorName}},

Subject: Post Marketing Surveillance Study of BEVETEX^®

BEVETEX is Paclitaxel Injection Concentrate for Nanodispersion containing 100 mg and 300 mg of paclitaxel. Bevetex is currently approved for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.Prior therapy should have included an anthracycline unless clinically contraindicated.

Although every new products is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planed to conduct a prospective study to assess the real-life performance of Bevetex.

We invite you to participate in this study. All you need to do is to report on a standard form your experience with Bevetex in 5 consecutive patients (to avoid any bias) in whom you prescribe this product in the normal course of your practice. Thus, this is not an experimental study because the product will be prescribed and purchased as you and your patients normally do.

If you agree to participate, you will need to copy the relevant information from these {{$numberOfPatient}} patients’ case papers, and investigational reports if any (which we call source documents), on to the standard case report forms (which we call CRF). A monitor will assist you in verifying the CRF with the source documents to ensure that the CRF signed by you are free from errors or omissions. Let us assure you that the CRF will not contain the patients’ names so as to ensure confidentiality.

If any serious adverse events (AE) occur during Bevetex therapy, you will be expected to report them to the monitor or to me immediately on the AE reporting form.

As you will be spending some extra time to keep, copy and verify these 5 patients’ records, we offer to pay you a professional fee of Rs. {{$contractAmount}}/- per patient on receiving the details Bevetex Rx (without any patient confidential data).

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.